---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-24-000006"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T07:31:02.307012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics reports FY2023 net loss $20.8M; cash $50.5M; ASCEND trial on track for Q4 2024 data

## Summary
- Net loss of $20.8M for FY2023 vs $54.2M in FY2022; operating expenses $25.7M (down 55% YoY).
- Cash, cash equivalents, and marketable securities of $50.5M; runway projected into early 2026.
- Phase 2b ASCEND trial in mPDAC fully enrolled; top-line data expected Q4 2024; complete data mid-2025.
- R&D expenses $12.7M vs $13.1M prior year; G&A expenses $13.0M vs $14.1M.
- Multiple Phase 2a trials ongoing (BOLSTER, CENDIFOX, iLSTA, GBM); Qilu licensee progressing in China.

## SEC filing metadata
- accession: 0000320017-24-000006
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/0000320017-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/clbs-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-24-000006
- JSON: https://secwatch.observer/filing/0000320017-24-000006.json
- Plain text: https://secwatch.observer/filing/0000320017-24-000006.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. updated its twelve months ended December 31, 2023 guidance (reaffirmed).
  - Period: twelve months ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001724000006/0000320017-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.